Asian Pricing and Reimbursement

Ju Hyoung Lim, PhD

How to compete and succeed in a rapidly changing market

A land of pharma opportunity and financial challenges

Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. This sea of change is also being driven by multiple factors including government healthcare reforms, increasing Universal Health Coverage (UHC), the rise of private financing and heavy promotion of the generic market.

This offers a significant opportunity both for established pharmaceutical companies in the region who wish to continue to thrive and for those considering entering the Asian market. However, it also presents a unique set of regional challenges and commercial success will be dependent on understanding the complexities of the Asian pricing and reimbursement environment.

Opportunities within a changing Asian market

The Asian healthcare landscape is a dynamic one. The region consists of a wide diversity of healthcare markets in very different stages of development, particularly with regard to their healthcare infrastructure.

The healthcare environment within Asia is changing dramatically and spending in the region has shown an explosive rise in recent decades. Between 2009-2012 Asian markets showed the highest growth of per-capita healthcare spending in the world, at 38.8% of CAGR compared with the global average of 26.3%.1 The sharp increase of healthcare spending in this region can be explained by several factors, including growing economies, expansion of the middle class, the rise of chronic illness and increased life expectancy.

To meet this rapid growth, Asian healthcare systems will need to expand and adapt. As more countries implement healthcare reforms, leading to greater patient population coverage, countries across Asia will need to address pricing and reimbursement challenges to meet healthcare demands.

Deallus Asian Pricing & Reimbursement Whitepaper
DOWNLOAD WHITE PAPER

About the author

Ju Hyoung Lim, PhD

Ju has played a pivotal role within Deallus to expand our presence in Asian markets, driving business growth throughout Singapore, Japan, and China. Ju works closely with clients in order to manage and support both regional and global projects. He has extensive experience in competitive intelligence, portfolio planning, indication scoping, forecasting, product planning, and workshop design.

More about Ju

You may also be interested in…

How is COVID-19 impacting clinical trials?

As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.

  • Deallus Announce New Strategic Advisor

Jennifer Cummins joins Deallus as Strategic Advisor

Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.

  • Deallus Announce New Senior Principal

Gloria Kwon Joins Deallus as Senior Principal

We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.

  • Peter Barschdorff joins Deallus as Vice President (U.S.)

Peter Barschdorff joins Deallus as Vice President (U.S.)

Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.